ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
Dow Jones
38,589.16
-0.15%
Brent Oil
82.275
0.00%
Bitcoin
66,170.62
0.25%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Prime Medicine Inc (PRME) Quote

Prime Medicine Inc

Prime Medicine Inc (PRME)

Prim SA
Prim SA
Prim SA
Prim SA
Prime Drink Group Corp
7.11
-0.79
(-10.00%)
Closed June 15 4:00PM
Delayed by 15 minutes
7.10
-0.01
(-0.14%)
After Hours: 7:22PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
7.10
Bid
5.00
Ask
9.45
Volume
668,196
7.072 Day's Range 7.92
4.11 52 Week Range 15.47
Market Cap
851.569M
Previous Close
7.90
Open
7.80
Last Trade
1
@
7.15
Last Trade Time
Financial Volume
$ 4,914,378
VWAP
7.3547
Average Volume (3m)
862,429
Shares Outstanding
119,939,247
Dividend Yield
-
PE Ratio
-4.30
Earnings Per Share (EPS)
-1.65
Revenue
-
Net Profit
-198.13M

About Prime Medicine Inc

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.primemedicine.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was $7.90. Over the last year, Prime Medicine shares have traded in a share price range of $ 4.11 to $ 15.47.

Prime Medicine currently has 119,939,247 shares outstanding. The market capitalization of Prime Medicine is $851.57 million. Prime Medicine has a price to earnings ratio (PE ratio) of -4.30.

PRME Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

8 hours ago
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 hours ago
Edgar (US Regulatory)

Form 8-K - Current report

June 12 2024
Edgar (US Regulatory)

Prime Medicine to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

May 30 2024
GlobeNewswire Inc.

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 21 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 21 2024
Edgar (US Regulatory)

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

May 13 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 10 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 10 2024
Edgar (US Regulatory)

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025...

May 10 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.446.606606606616.668.14426.5210477437.51837483CS
40.050.7092198581567.058.276.039927567.1130995CS
12-0.24-3.269754768397.348.274.118624296.19633937CS
26-1.87-20.84726867348.979.864.117478066.99196044CS
52-7.7-52.02702702714.815.474.116066218.39165875CS
156-11.87-62.572482867718.9721.73014.1146823410.00429845CS
260-11.87-62.572482867718.9721.73014.1146823410.00429845CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

PRME Discussion

View Posts
Monksdream Monksdream 2 weeks ago
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
👍️0
Monksdream Monksdream 3 weeks ago
PRME under $10
👍️0
jondoeuk jondoeuk 3 weeks ago
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
👍️0
NY1972 NY1972 2 months ago
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
👍️0
jondoeuk jondoeuk 2 months ago
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
👍️0
jondoeuk jondoeuk 4 months ago
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
👍️0

Your Recent History

NASDAQ
PRME
Prime Medicine
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved